A new chapter in Alzheimer’s disease treatment is being written with a landmark $600 million agreement between South Korea’s AriBio and UAE-based Arcera, a pharmaceutical company under the country’s sovereign wealth fund. The partnership grants Arcera exclusive rights to commercialize AR1001, AriBio’s investigational oral Alzheimer’s drug, across Latin America, the Middle East, Africa, Ukraine, and select Eurasian markets.
Arcera, which distributes over 2,000 products to more than 90 countries, is expanding its neuroscience portfolio through this deal, reinforcing its commitment to accessible innovation. With AR1001, the company plans to accelerate its entry into emerging markets where demand for neurological treatments is growing rapidly.
Also Read: Fujirebio Diagnostics’ Alzheimer’s Blood Test Cleared by FDA
AR1001, currently in global Phase 3 trials, is a once-daily, disease-modifying therapy for early-stage Alzheimer’s. As a phosphodiesterase-5 (PDE5) inhibitor, the drug is designed to stimulate the growth of neuronal cells, clear toxic protein build-up in the brain, and improve cerebral blood flow—all of which are key challenges in managing Alzheimer’s disease. Originally developed by SK Chemicals, AR1001 was licensed to AriBio in 2011, which has since led its clinical development.
The agreement was formalized just ahead of the anticipated topline results from the POLARIS-AD trial, with patient enrollment already completed—surpassing expectations with 1,500 participants enrolled across 13 countries.
“This contract, signed ahead of the topline (key indicator) announcement for the Phase 3 clinical trial scheduled for the first half of next year, is a meaningful achievement demonstrating the Middle Eastern sovereign wealth fund’s strong confidence in AR1001’s potential for success and commercialization,” an AriBio official said.
The total value of AriBio’s licensing agreements for AR1001 now amounts to approximately KRW 1.94 trillion (USD 1.4 billion), following earlier deals with Samjin Pharmaceutical in South Korea and a major Chinese firm. This latest partnership with Arcera was facilitated through the Korea Development Bank’s global partnership support program and aligns with the Korean government’s push to elevate the nation’s biohealth sector.
“Arcera has a deep understanding of the Alzheimer’s disease treatment market and strong commercialization capabilities, making them the optimal partner to ensure that patients in the contracted regions can benefit maximally from AR1001 after its clinical success,” said Choung Jai-jun, CEO of AriBio. “With this contract as a turning point, we will successively secure exclusive sales rights contracts with global companies currently in negotiations for major markets such as Europe, the United States, and Japan.”
Isabel Afonso, CEO of Arcera, added: “This contract aligns with our strategy to expand our neuroscience pipeline and demonstrates Arcera’s commitment to providing innovative treatment options for Alzheimer’s disease patients with limited access to treatment. We hope that AR1001 can be delivered to patients worldwide more quickly.”
AriBio’s work with Arcera is not only a significant business move but a hopeful stride forward in the fight against one of the most devastating neurodegenerative diseases of our time. As topline data for AR1001 approaches, the world watches with anticipation—and patients in underserved regions may soon have renewed hope.
